PathAI Diagnostics的动态

In our commitment to improving diagnosis of cancer and other diseases, PathAI has formed a multifaceted collaboration with Quest Diagnostics?to accelerate the adoption of digital pathology and AI. Together with Quest’s expertise and scale, our collaboration represents a significant milestone for the anatomic pathology industry and marks a major turning point for digital pathology adoption in the U.S. and beyond. Highlights: ? · Quest will license PathAI's best-in-class AISight? IMS and algorithm portfolio to support its pathology laboratories and customer sites in the United States. · Under a separate agreement, Quest will acquire PathAI Diagnostics, which will become Quest’s AI and digital R&D and solutions center?in Memphis, Tennessee. · PathAI’s Biopharma Lab, which is separate and distinct from the diagnostic laboratory business, will continue to support its biopharma clients with end-to-end clinical trial services capabilities; Quest will become a preferred partner for PathAI on biopharma collaborations. ·?Quest and PathAI may explore opportunities to evolve PathAI's algorithm product offering. ? PathAI's unique IMS, algorithm portfolio, and digital innovations are reshaping workflow and quality standards at pathology laboratories, helping address customers’ need for more efficient and high-quality pathology operations. Together with our partners, we are dedicated to improving patient outcomes with our AI powered technology and insights. ? Read more here. https://lnkd.in/e8ES2-mA #AI #Pathology #AIPoweredPathology #DigitalInnovation #HealthcareInnovation #Progress #Patients